Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Funding
$1.0M
Deadline
--
Days
--
Hrs
--
Min
--
Sec
May 07, 2028
Posted Dec 30, 2024 (417 days ago)
Closes May 7, 2028 (in 806 days)
Grant Details
Opportunity Number
PAR-25-374
CFDA / ALN
93.866
Opportunity Category
Discretionary (D)
Funding Category
Health (HL)
Funding Instrument
Grant (G)
Cost Sharing
No Cost Sharing (No)
Eligibility
State governments (00)
County governments (01)
City or township governments (02)
Special district governments (04)
Independent school districts (05)
Public and State controlled institutions of higher education (06)
Native American tribal governments (Federally recognized) (07)
Public housing authorities / Indian housing authorities (08)
Native American tribal organizations (11)
Nonprofits having a 501(c)(3) status with the IRS (12)
Nonprofits without 501(c)(3) status (13)
Private institutions of higher education (20)
For-profit organizations other than small businesses (22)
Small businesses (23)
Others (25)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description
This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.
Related Grants
Cooperative Agreement for affiliated Partner with the North Atlantic Coast Cooperative Ecosystem Studies Unit
Geological Survey
$498,392
New World Screwworm Grand Challenge
Animal and Plant Health Inspection Service
$5,000,000
FY 2026 National Infrastructure Investments
69A345 Office of the Under Secretary for Policy
$25,000,000
OVC FY25 Preventing Trafficking of Girls
Office for Victims of Crime
$497,000
OVC FY25 Specialized Human Trafficking Assistance: Supporting Survivor Engagement in Anti-Trafficking Programming
Office for Victims of Crime
$1,200,000
OVC FY25 Integrated Services for Minor Victims of Human Trafficking
Office for Victims of Crime
$950,000